New study aims to map rare muscle disease progression
NCT ID NCT06210672
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to track the natural course of gamma-sarcoglycanopathy (LGMDR5), a rare muscle-weakening disease, over two years. Researchers planned to measure changes in muscle strength, walking ability, and daily function in patients aged 6 to 35. The goal was to better understand the disease to help design future treatments. However, the study was withdrawn before enrolling any participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GAMMA-SARCOGLYCANOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hedi Chaker Hospital Child Neurology Department
Sfax, Tunisia
-
Hopital Raymond Poincare
Garches, 92380, France
-
National Institute Mongi Ben Hmida of Neurology
Tunis, Tunisia